IRLAB Therapeutics (OMX: IRLAB-A)

Last close As at 27/03/2024

SEK16.20

−0.55 (−3.28%)

Market capitalisation

SEK868m

Based in Sweden, IRLAB Therapeutics is focused on developing novel drugs for the treatment of neurodegenerative diseases utilising its ISP technology platform. Its two lead assets, mesdopetam and pirepemat, are in late-stage clinical trials for the symptomatic treatment of Parkinson’s disease (PD).

PD is characterised by a triad of cardinal motor symptoms, although non-motor symptoms are as debilitating and remain undertreated. Despite substantial efforts to develop disease-modifying approaches in PD, symptomatic treatment remains the mainstay.

Latest Insights

View More
IRLAB Therapeutics_resized

Sector

Healthcare

Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Nidhi Singh

Nidhi Singh

Analyst

Arron Aatkar

Associate analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Viktor Siewertz

    CFO

Balance Sheet

Forecast net cash (SEKm)

74.2

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
% 1M 3M 12M
Actual 13.6 161.7 46.4
Relative 7.3 140.5 18.7
52 week high/low SEK19.6/SEK5.9

Financials

IRLAB Therapeutics has confirmed the FDA’s alignment with its proposed Phase III programme for mesdopetam in levodopa-induced dyskinesias (PD-LIDs), following receipt of the minutes from its end-of-Phase II (EoP2) meeting held last month. Notably, the FDA has agreed on the primary endpoint being the Unified Dyskinesia Rating Scale (UDysRS), on which mesdopetam demonstrated a statistically significant improvement (p=0.026) in the Phase IIb study (secondary endpoint of that study). IRLAB will now engage with European regulatory agencies to prepare for the Phase III trial. Following the positive endorsement from the FDA, we expect partnering talks to intensify in the coming weeks, with the partner taking on responsibility for further clinical development.

Y/E Dec Revenue (SEKm) EBITDA (SEKm) PBT (SEKm) EPS (öre) P/E (x) P/CF (x)
2022A 61.3 (108.3) (113.1) (218.0) N/A N/A
2023A 5.7 (176.5) (177.8) (343.0) N/A N/A
2024E 0.0 (185.5) (191.3) (369.0) N/A N/A
2025E 0.0 (173.6) (189.7) (366.0) N/A N/A

Flash note

Healthcare

IRLAB Therapeutics — On track for pirepemat in Phase IIb

edison tv

Healthcare

IRLAB Therapeutics – executive interview

IRLAB Therapeutics_resized

Update

Healthcare

IRLAB Therapeutics — Don’t count mesdopetam out

Flash note

Healthcare

IRLAB Therapeutics — Cautious update on portfolio timelines

IRLAB Therapeutics_resized

Flash note

Healthcare

IRLAB Therapeutics — Mesdopetam Phase IIb top-line data

edison tv

Healthcare

IRLAB Therapeutics – executive interview

Flash note

Healthcare

IRLAB Therapeutics — Phase IIb recruitment complete

flag

Flash note

Healthcare

IRLAB Therapeutics — Richard Godfrey appointed as new CEO

edison tv

Healthcare

IRLAB Therapeutics – executive interview

DSF9408

Update

Healthcare

IRLAB Therapeutics — Looking beyond mesdopetam

edison tv

Healthcare

IRLAB Therapeutics AB: Edison Open House Healthcare 2022

Update

Healthcare

IRLAB Therapeutics — Ipsen deal de-risks the strategy

DSF9408

Flash note

Healthcare

IRLAB Therapeutics — Global licensing deal for mesdopetam